Lv3
340 积分 2023-10-20 加入
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
17天前
已完结
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS
24天前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?
24天前
已关闭
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
25天前
已完结
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?
25天前
已关闭
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies
26天前
已关闭
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
28天前
已完结
Risk stratification and early intervention in smoldering multiple myeloma
29天前
已完结
Reshaping multiple myeloma treatment: recent breakthroughs
29天前
已完结
Risk stratification and early intervention in smoldering multiple myeloma
29天前
已关闭
皖公网安备34019202002308
